Lung Cancer: One Therapy is better than Two Sequential Therapies

Mohamed Emam
Additional contact information
Mohamed Emam: Cairo University, Egypt

Cancer Therapy & Oncology International Journal, 2018, vol. 9, issue 2, 55-56

Abstract: Lung cancer is the leading cause of cancer death among men and women, accounting for about one-third of all cancer deaths, more than breast, prostate and colorectal cancers combined [1]. 10% to 15% of these are EGFR mutation-positive. Approximately two-thirds of patients treated with EGFR TKI therapy will acquire resistance related to the T790M mutation. Further investigations demonstrated that the highest response rates to these TKIs were seen in patients with somatic mutations within the EGFR-TK domain, particularly exon 19 deletion, exon 21 L858R, and exon 18 G719X [2].

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555759.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555759.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:9:y:2018:i:2:p:55-56

DOI: 10.19080/CTOIJ.2018.09.555759

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().